Bal Pharma Ltd vs Rubicon Research Ltd Stock Comparison
Bal Pharma Ltd vs Rubicon Research Ltd Stock Comparison
Last Updated on: May 03, 2026
Key Highlights
The Latest Trading Price of Bal Pharma Ltd is ₹ 75.6 as of 30 Apr 15:30
. The P/E Ratio of Bal Pharma Ltd changed from 16.8 on March 2021 to 18.4 on March 2025 . This represents a CAGR of 1.84% over 5 yearsThe P/E Ratio of Rubicon Research Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bal Pharma Ltd changed from ₹ 79.67 crore on March 2021 to ₹ 132.4 crore on March 2025 . This represents a CAGR of 10.69% over 5 yearsThe Market Cap of Rubicon Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Bal Pharma Ltd for the Dec '25 is ₹ 88.02 crore as compare to the Sep '25 revenue of ₹ 75.14 crore. This represent the growth of 17.14% The revenue of Rubicon Research Ltd for the Dec '25 is ₹ 479.32 crore as compare to the Sep '25 revenue of ₹ 412.72 crore. This represent the growth of 16.14% The ebitda of Bal Pharma Ltd for the Dec '25 is ₹ 9.87 crore as compare to the Sep '25 ebitda of ₹ 6.85 crore. This represent the growth of 44.09% The ebitda of Rubicon Research Ltd for the Dec '25 is ₹ 111.91 crore as compare to the Sep '25 ebitda of ₹ 94.99 crore. This represent the growth of 17.81% The net profit of Bal Pharma Ltd changed from ₹ 0.26 crore to ₹ 1.79 crore over 7 quarters. This represents a CAGR of 201.15%
The net profit of Rubicon Research Ltd changed from ₹ 25.57 crore to ₹ 72.8 crore over 7 quarters. This represents a CAGR of 81.83%
The Dividend Payout of Bal Pharma Ltd changed from 16.29 % on March 2021 to 24.49 % on March 2025 . This represents a CAGR of 8.50% over 5 yearsThe Dividend Payout of Rubicon Research Ltd changed from -1.5 % on March 2023 to 0.18 % on March 2025 . This represents a CAGR of NaN% over 3 years .
About Bal Pharma Ltd
Bal Pharma Limited (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 1987.
In March 1990, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.
BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc.
The company promotes its products through the common sales force of the group but proposes to induct its own soon.
It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.
About Rubicon Research Ltd
Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002.
The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'.
A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana.
Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products.
FAQs for the comparison of Bal Pharma Ltd and Rubicon Research Ltd
Which company has a larger market capitalization, Bal Pharma Ltd or Rubicon Research Ltd?
Market cap of Bal Pharma Ltd is 120 Cr while Market cap of Rubicon Research Ltd is 15,985 Cr
What are the key factors driving the stock performance of Bal Pharma Ltd and Rubicon Research Ltd?
The stock performance of Bal Pharma Ltd and Rubicon Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bal Pharma Ltd and Rubicon Research Ltd?
As of May 3, 2026, the Bal Pharma Ltd stock price is INR ₹75.6. On the other hand, Rubicon Research Ltd stock price is INR ₹970.3.
How do dividend payouts of Bal Pharma Ltd and Rubicon Research Ltd compare?
To compare the dividend payouts of Bal Pharma Ltd and Rubicon Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.